Navigation Links
MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films

WARREN, N.J., Nov. 9, 2010 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,824,588 from the United States Patent and Trademark Office (USPTO). The patent, issued on November 2, 2010, provides intellectual property protection for the Company's film products and methods of their preparation.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Our patented PharmFilm® and production technologies are very important to ensuring that drug containing films are manufacturable, content uniform, stable and deliver the in-vivo performance that is expected from each and every dose.  Importantly, this patent also signals to the entire pharmaceutical industry that PharmFilm® is an ideal vehicle for delivering a variety of dosage strengths and sensitive prescription drug targets, including peptides and proteins as well as small molecules."

Mr. Schobel continued, "Our patent estate continues to strategically grow thereby affording us and our partners a strong and protected product position within the market."

Keith Kendall, executive vice president and CFO of MonoSol Rx said, "We are a technology company, a partnering company and an innovator.  Our strategy is to apply our technology, alone or in combination with others, to add value to our current and prospective partners.  Continuing to innovate and thereby expand the value and applicability of our PharmFilm® platform is critical to the success of MonoSol Rx.  As such, we invest significant time and resources to broaden and protect our intellectual property, and we believe this latest patent gives us, and by extension our partners, significant competitive advantage."

About MonoSol RxMonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  sublingual film, the first combination sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing.  For existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).  For press releases and other company information visit Contacts:MonoSol Rx:Keith KendallChief Financial Officer(732) 564-5000The Ruth Group (on behalf of MonoSol Rx)Jason Rando (media)(646)  Sara Pellegrino (investors)(646)  

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
2. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
3. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
4. Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
5. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
6. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
7. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
8. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
9. Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent
10. Sixth U.S. Patent Issued to Dyadic International
11. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
Post Your Comments:
(Date:11/27/2015)... --> --> ... The potential to save costs, improve treatment quality and ... fully exploited as yet. Here, particular emphasis is placed ... mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... , Nov. 26, 2015 ... addition of the "2016 Global Tumor ... Country Volume and Sales Segment Forecasts, Innovative ... report to their offering. --> ... of the "2016 Global Tumor Marker ...
(Date:11/26/2015)... November 26, 2015 --> ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... has found that immunotherapy can be efficiently combined with ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) ... supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
Breaking Medicine News(10 mins):